Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …

Patient-reported outcomes (PROs) for patients with myelofibrosis (MF) have been well
characterized, but little is known about quality of life (QoL) following allogeneic stem cell …

Background The prognostic significance of myelofibrosis (MF) grade in patients with
myelodysplastic syndrome (MDS) following an allogeneic hematopoietic stem cell …

Objective The role of allogenic stem cell transplantation (ASCT) is still debated in
myelofibrosis (MF). Methods A retrospective analyzed was performed to compare the …

This is a retrospective analysis of 95 patients with myelofibrosis who were allografted
between 2001 and 2014. The aims of the study were to assess whether the outcome of …

Optimal conditioning regimens for older patients with myelofibrosis undergoing allogeneic
hematopoietic cell transplant are not known. Likewise, the role of dose intensity is not clear …

Allogeneic hematopoietic cell transplantation (HCT) is commonly associated with hepatic
complications. Patients with myelofibrosis (MF) often develop liver dysfunction in the early …

Heterogeneous practices exist across transplant centres regarding assessment prior to
allogeneic haematopoietic cell transplantation (allo-HCT) for myelofibrosis, post-transplant …

Moving from indication to transplantation is a critical process in myelofibrosis. Most of
guidelines specifically focus on either myelofibrosis disease or transplant procedure, and …

Morel, P., Duhamel, A., Hivert, B., Stalnikiewicz, L., Demory, JL & Dupriez, B.(2010)
Identification during the follow-up of timedependent prognostic factors for the competing …